Replies to post #54180 on Biotech Values

[DewDiligence]

>ultimately, there will be fewer refractory patients to treat due to the improvement in treatment-naive.<

Quite so; however, until the bolus of existing treatment-refractory patients is whittled down, this setting will continue to be a large unmet need.